Investigating how certain proteins affect cognitive decline from trichloroethylene exposure in Parkinson's disease.
Official title: The role for cell cycle regulators in trichloroethylene induced Parkinson's dementia
Funded at University of Alabama at Birmingham · NIH-10996674 · Data updated 2026-11-12
This study is looking at how a chemical called trichloroethylene might affect thinking and memory problems in people with Parkinson's disease dementia, and it aims to find out how certain proteins in the brain could be involved in this process, all to help improve treatments for those dealing with these challenges.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $40,264 |
| NIH project number | 1F31ES036890-01 |
| Project ID | NIH-10996674 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals exposed to trichloroethylene and experiencing cognitive impairments or at risk for Parkinson's disease dementia.
✕Less likely to help
Patients who have not been exposed to trichloroethylene or do not have cognitive impairments related to Parkinson's disease may not benefit from this research.
What this research studies
This research focuses on understanding the impact of trichloroethylene, a chemical commonly found in industrial solvents, on cognitive impairments associated with Parkinson's disease dementia. The study will explore the role of specific proteins that regulate the cell cycle, particularly how their abnormal activation may contribute to cognitive decline. By using animal models, researchers will assess the mechanisms behind these cognitive deficits, aiming to uncover new insights into environmentally induced neurodegenerative diseases. This work is part of a broader effort to develop effective interventions for those affected by such conditions.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for preventing or treating cognitive decline in patients exposed to harmful environmental toxins.
How similar studies have gone: Previous research has shown promising results in understanding the effects of environmental toxins on neurodegenerative diseases, suggesting that this approach could yield valuable insights.
Where this research is happening
-
University of Alabama at Birmingham
Birmingham, United States Active
Researchers
- Principal investigator: Adamson, Ashley — University of Alabama at Birmingham
- Study coordinator: Adamson, Ashley
Related research
Other NIH-funded projects on the same topics.
-
Investigating how DNA damage and repair mechanisms are altered in ALS and frontotemporal dementia.
This study is looking at how problems with DNA repair might contribute to conditions like ALS and frontotemporal dementia, and it’s testing ways to fix these issues in cells from patients to help develop new treatments.
-
Synthetic protein mimetics to treat Lewy Body Dementia
A new therapeutic approach using engineered protein-like molecules to block the harmful protein clumps that cause Lewy Body Dementia.
-
Dementia care staff study: adapting a US survey for use in many countries
A study is adapting and testing a survey for dementia care workers in the US, Brazil, Switzerland, and Ghana to help understand why workers stay in their jobs and how to improve care.
-
Dementia care staff study: adapting a survey for use in many countries
A multinational study will adapt and test a U.S. dementia-care worker survey in Brazil, Switzerland, and Ghana to help understand why staff stay in or leave long-term care settings.
-
Study of Dementia Care Staff in 4 Countries: Adapting Caregiver Surveys Across Cultures
A multinational project will adapt and test a dementia care worker survey so researchers can compare care environments across the US, Brazil, Switzerland, and Ghana.
-
New biomarkers to distinguish LATE from Alzheimer’s disease in dementia
A study to develop blood and CSF tests that can tell apart LATE from Alzheimer’s disease in people with dementia.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.